Breaking News Instant updates and real-time market news.

RCKT

Rocket Pharmaceuticals

$22.37

2.61 (13.21%)

18:05
12/08/19
12/08
18:05
12/08/19
18:05

Rocket says Phase 1 trial establishes feasibility of commercial Process B for FA

Rocket Pharmaceuticals announced "encouraging" preliminary results from its Phase 1 trial of commercial-grade RP-L102 "Process B" for Fanconi Anemia, or FA, at the 61st American Society of Hematology Annual Meeting. Results presented in the poster highlight preliminary Phase 1 data from two pediatric patients who were treated with "Process B" RP-L102 prior to the development of severe bone marrow failure and are in ongoing follow-up. Drug product was successfully manufactured using "Process B" optimization, including transduction enhancers, commercial-grade vector and modified cell processing. "Process B" drug product is manufactured to commercial grade standards, allowing for consistent drug product across patients and a vector copy number two to three fold higher than that administered to optimally-treated "Process A" patients. Once transduced, drug product was infused fresh into patients without any prior conditioning regimen. To evaluate transduction efficiency, an analysis of the proportion of the MMC-resistant colony forming cells was conducted. Both patients exhibited early signs of engraftment based on peripheral blood, VCN and/or MMC-resistance. Preliminary phenotypic correction was also apparent in both patients, as evidenced by stabilization or increases in blood cell lineages. No safety or tolerability issues have been reported. "The preliminary data presented at ASH provide evidence regarding the potential of our commercial-grade 'Process B' product in treating FA," said Gaurav Shah, M.D., Chief Executive Officer and President of Rocket. "Treatment with 'Process B' RP-L102 at four to six months post-infusion showed early signs of engraftment and bone marrow restoration. Further, previously declining blood cell counts appear to have been stabilized or even increased within six months of therapy, providing evidence regarding the potential benefits of treatment with a consistent, commercial-grade product. We are looking forward to presenting additional long-term follow-up data from these patients in the first half of 2020."

  • 08

    Dec

  • 08

    Dec

RCKT Rocket Pharmaceuticals
$22.37

2.61 (13.21%)

11/05/19
CHDN
11/05/19
INITIATION
Target $30
CHDN
Buy
Rocket Pharmaceuticals initiated with a Buy at Chardan
Chardan analyst Geulah Livshits initiated coverage of Rocket Pharmaceuticals with a Buy rating and $30 price target citing the potential of its blended ex vivo/in vivo gene therapy pipeline. The analyst said Rocket is rapidly advancing its pipeline with 4 company sponsored INDs cleared within the last 12 months to provide transformative treatments for patients with rare monogenic diseases and shareholder value through inflection points.
11/07/19
PIPR
11/07/19
NO CHANGE
Target $35
PIPR
Overweight
Rocket Pharmaceuticals data by year-end to boost shares, says Piper Jaffray
Piper Jaffray analyst Tyler Van Buren believes "positive" Process B Fanconi anemia data and positive initial Phase I LAD-1 data by year-end will boost shares of Rocket Pharmaceuticals higher. Sales from Rocket's lentiviral pipeline alone could exceed $1B, while the Danon's disease program has blockbuster potential of $3B or more, Van Buren tells investors in a research note. He keeps an Overweight rating on Rocket Pharmaceuticals with a $35 price target following the company's Q3 results.
11/18/19
PIPR
11/18/19
NO CHANGE
Target $35
PIPR
Overweight
Rocket may be next leading lentiviral vector company, says Piper Jaffray
After hosting an investor lunch with management, Piper Jaffray analyst Tyler Van Buren says Rocket Pharmaceuticals could "soon take the spot as the next leading lentiviral vector company." By year-end, the analyst expects early clinical observations from the two Process B Fanconi anemia patients and the one LAD-1 patient to give insight into the likely approvability of these programs. The Fanconi anemia update doesn't just de-risk an addressable opportunity that is approaching $1B, it validates Rocket's broader lentiviral gene therapy platform, Van Buren tells investors in a research note. He keeps an Overweight rating on the shares with a $35 price target.
12/06/19
BARD
12/06/19
NO CHANGE
Target $41
BARD
Outperform
Rocket Pharmaceuticals elevated to Fresh Pick, target raised to $41 at Baird
Baird analyst Madhu Kumar said his optimism on Rocket Pharmaceuticals leads him to raise his price target to $41 from $30 ahead of the release of its ASH data on December 08. He also raised his launch probability to 30% and elevated the shares to Fresh Pick. Kumar reiterated his Outperform rating on Rocket Pharmaceuticals shares.

TODAY'S FREE FLY STORIES

03:30
01/20/20
01/20
03:30
01/20/20
03:30
General news
FX Action: USD-CAD ebbed fractionally lower »

FX Action: USD-CAD ebbed…

03:05
01/20/20
01/20
03:05
01/20/20
03:05
General news
Asian Market Update: »

Asian Market Update:…

03:05
01/20/20
01/20
03:05
01/20/20
03:05
General news
FX Update: The dollar has seen modest weakness »

FX Update: The dollar has…

FB

Facebook

$222.01

0.23 (0.10%)

16:50
01/19/20
01/19
16:50
01/19/20
16:50
Periodicals
Facebook blames technical error for vulgar translation, Reuters reports »

Facebook blamed a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 29

    Jan

SPY

SPDR S&P 500 ETF Trust

$331.98

1.08 (0.33%)

, SPX

S&P 500

$0.00

(0.00%)

16:43
01/19/20
01/19
16:43
01/19/20
16:43
Periodicals
China to increase U.S. imports according to 'market principles,' Reuters reports »

China will negotiate with…

SPY

SPDR S&P 500 ETF Trust

$331.98

1.08 (0.33%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSLA

Tesla

$510.34

-3.065 (-0.60%)

16:33
01/19/20
01/19
16:33
01/19/20
16:33
Periodicals
Tesla closer to opening first European factory with property deal, Reuters says »

Tesla has agreed to buy a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

  • 24

    Feb

  • 23

    Mar

  • 23

    Mar

JPM

JPMorgan

$138.15

0.89 (0.65%)

, BNPQY

BNP Paribas

$0.00

(0.00%)

16:28
01/19/20
01/19
16:28
01/19/20
16:28
Periodicals
JPMorgan to acquire former BNP building in Paris, Bloomberg reports »

JPMorgan (JPM) is buying…

JPM

JPMorgan

$138.15

0.89 (0.65%)

BNPQY

BNP Paribas

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Feb

  • 25

    Feb

  • 14

    Apr

BAC

Bank of America

$34.70

-0.03 (-0.09%)

16:25
01/19/20
01/19
16:25
01/19/20
16:25
Periodicals
CEO tells FT Bank of America aims to 'double' slice of U.S. retail business »

Bank of America can…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 15

    Apr

CEL

Cellcom Israel

$3.18

(0.00%)

16:16
01/19/20
01/19
16:16
01/19/20
16:16
Hot Stocks
Cellcom Israel announces CTO resignation »

Cellcom Israel announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VRCA

Verrica Pharmaceuticals

$15.94

0.21 (1.34%)

16:12
01/19/20
01/19
16:12
01/19/20
16:12
Hot Stocks
Verrica announces presentation of data from Phase 3 CAMP trials of VP-102 »

Verrica Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Jul

SO

Southern Company

$67.25

1.08 (1.63%)

, XEL

Xcel Energy

$65.38

0.34 (0.52%)

16:08
01/19/20
01/19
16:08
01/19/20
16:08
Hot Stocks
Southern Power closes sale of Mankato Energy Center to Xcel Energy »

Southern Power, a…

SO

Southern Company

$67.25

1.08 (1.63%)

XEL

Xcel Energy

$65.38

0.34 (0.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

LIZI

Lizhi

$11.72

(0.00%)

, DNK

Phoenix Tree

$13.50

(0.00%)

09:10
01/19/20
01/19
09:10
01/19/20
09:10
On The Fly
Opening Day: China's Lizhi, Phoenix Tree flat in trading debut »

Lizhi (LIZI), one of…

LIZI

Lizhi

$11.72

(0.00%)

DNK

Phoenix Tree

$13.50

(0.00%)

VEL

Velocity Financial

$13.58

(0.00%)

IMAB

I-MAB

$12.90

(0.00%)

BSBK

Bogota Financial

$11.70

0.195 (1.70%)

CSPR

Casper Sleep

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TLGT

Teligent

$0.40

-0.0025 (-0.62%)

15:53
01/18/20
01/18
15:53
01/18/20
15:53
Conference/Events
Teligent to hold a special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

AYTU

Aytu BioScience

$0.80

0.0014 (0.18%)

15:48
01/18/20
01/18
15:48
01/18/20
15:48
Conference/Events
Aytu BioScience to hold a special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

DVA

DaVita

$79.45

0.43 (0.54%)

15:32
01/18/20
01/18
15:32
01/18/20
15:32
Conference/Events
DaVita to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

TSM

TSMC

$58.58

-0.18 (-0.31%)

09:16
01/18/20
01/18
09:16
01/18/20
09:16
Periodicals
Taiwan tech stocks can ignore China's bluster for now, Barron's says »

China's government…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KKR

KKR

$31.20

0.7 (2.30%)

, APO

Apollo Global

$50.35

1.26 (2.57%)

09:03
01/18/20
01/18
09:03
01/18/20
09:03
Periodicals
KKR undervalued compared with peers, Barron's says »

KKR (KKR) gained 50% last…

KKR

KKR

$31.20

0.7 (2.30%)

APO

Apollo Global

$50.35

1.26 (2.57%)

ARES

Ares Management

$37.29

0.47 (1.28%)

BX

Blackstone

$60.79

0.62 (1.03%)

CG

Carlyle Group

$33.30

0.36 (1.09%)

HLNE

Hamilton Lane

$67.25

-0.02 (-0.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

  • 30

    Jan

  • 31

    Jan

  • 31

    Jan

  • 04

    Feb

  • 04

    Feb

  • 05

    Feb

  • 13

    Feb

  • 17

    Feb

  • 26

    Feb

SPCE

Virgin Galactic

$15.65

0.685 (4.58%)

, TWNK

Hostess Brands

$14.03

0.02 (0.14%)

08:56
01/18/20
01/18
08:56
01/18/20
08:56
Periodicals
'Blank-check' companies hot on Wall Street, Barron's says »

More than a quarter of…

SPCE

Virgin Galactic

$15.65

0.685 (4.58%)

TWNK

Hostess Brands

$14.03

0.02 (0.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 04

    Mar

GOOG

Alphabet

$1,480.28

28.34 (1.95%)

, NFLX

Netflix

$339.56

0.89 (0.26%)

08:47
01/18/20
01/18
08:47
01/18/20
08:47
Periodicals
Peacock's pricing might be 'killer feature,' Barron's says »

This week, Peacock…

GOOG

Alphabet

$1,480.28

28.34 (1.95%)

NFLX

Netflix

$339.56

0.89 (0.26%)

CMCSK

Comcast

$0.00

(0.00%)

CMCSA

Comcast

$47.48

0.62 (1.32%)

GOOGL

Alphabet Class A

$1,479.12

29.29 (2.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

  • 22

    Jan

  • 23

    Jan

  • 03

    Feb

  • 03

    Feb

  • 10

    Feb

JWN

Nordstrom

$40.34

-0.15 (-0.37%)

, WMT

Walmart

$114.93

-0.96 (-0.83%)

08:36
01/18/20
01/18
08:36
01/18/20
08:36
Periodicals
Casper IPO highlights tech's promise, troubles, Barron' says »

Mattresses have been…

JWN

Nordstrom

$40.34

-0.15 (-0.37%)

WMT

Walmart

$114.93

-0.96 (-0.83%)

CSPR

Casper Sleep

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

  • 18

    Feb

BA

Boeing

$324.11

-7.89 (-2.38%)

, DDAIF

Daimler AG

$0.00

(0.00%)

08:12
01/18/20
01/18
08:12
01/18/20
08:12
On The Fly
Week in Review: How Trump's policies moved stocks »

Catch up on the top…

BA

Boeing

$324.11

-7.89 (-2.38%)

DDAIF

Daimler AG

$0.00

(0.00%)

FCAU

Fiat Chrysler

$13.76

-0.14 (-1.01%)

VWAGY

Volkswagen

$0.00

(0.00%)

FSLR

First Solar

$53.51

-0.42 (-0.78%)

AAPL

Apple

$318.66

3.33 (1.06%)

DQ

Daqo New Energy

$53.61

-0.025 (-0.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jan

  • 29

    Jan

SPOT

Spotify

$148.20

-3.59 (-2.37%)

18:15
01/17/20
01/17
18:15
01/17/20
18:15
Periodicals
Spotify in talks to acquire The Ringer, WSJ reports »

Spotify is in discussions…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Feb

CE

Celanese

$117.54

-0.53 (-0.45%)

18:00
01/17/20
01/17
18:00
01/17/20
18:00
Hot Stocks
Celanese announces acetyl intermediates price increases »

Celanese Corporation will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jan

BYND

Beyond Meat

$109.20

-1.16 (-1.05%)

17:58
01/17/20
01/17
17:58
01/17/20
17:58
Periodicals
Beyond Meat rival gets green light in Canada, The Star says »

Impossible Foods, a maker…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DBD

Diebold

$11.09

-0.49 (-4.23%)

17:42
01/17/20
01/17
17:42
01/17/20
17:42
Periodicals
Breaking Periodicals news story on Diebold »

Diebold Nixdorf divests…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.